Supplementary Material for: Three-Year Clinical Outcome of Patients with Coronary Disease and Increased Event Risk Treated with Newer-Generation Drug-Eluting Stents: From the Randomized DUTCH PEERS Trial

Objective: Limited data is available on the long-term
outcome of patients with increased cardiovascular event risk, treated
with newer-generation durable polymer drug-eluting stents (DES). Methods:
We therefore assessed 3-year follow-up data of high-risk versus low- to
intermediate-risk patients of the randomized DUTCH PEERS trial
(NCT01331707). In both risk groups we also compared patients treated
with Resolute Integrity versus Promus Element DES. Patients were
categorized as “high-risk” if they met ≥1 of the following criteria: (1)
diabetes (17.9%); (2) previous myocardial infarction (21.9%); (3)
previous coronary revascularization (25.8%); (4) chronic renal failure
(3.5%); (5) left ventricular ejection fraction ≤30% (1.5%); and (6) age
≥75 years (17.3%). Results: At the 3-year follow-up, the incidence of the composite endpoint target vessel failure (TVF) (13.2 vs. 7.5%; logrank p < 0.001) and 2 of its components - cardiac death (4.7 vs. 1.5%; logrank p < 0.001) and target vessel revascularization (7.3 vs. 4.7%; logrank p = 0.03) - was higher in high-risk (n = 957) versus low- to intermediate-risk patients (n = 854). Among high-risk patients, treatment with Resolute Integrity (n = 481) and Promus Element stents (n = 476) was similarly safe and efficacious (TVF: 13.3 vs. 13.1%; logrank p = 0.95; definite-or-probable stent thrombosis: 1.7 vs. 1.7%; logrank p = 1.00). Conclusions:
The newer-generation Resolute Integrity and Promus Element stents
showed similar results in terms of safety and efficacy for treating
high-risk patients, who had significantly higher event rates than
patients with low-to-intermediate risk.